Business Context and Reporting Period
This Form 6-K filing by Tower Semiconductor Ltd. (TowerJazz) covers the period of March 5, 2019. The filing serves as a press release announcing a strategic technological milestone rather than a periodic financial report.
Key Financial Metrics
The filing text does not provide specific financial data, including revenue, profit, cash flow, margins, debt, or liquidity figures. This document focuses exclusively on a product development announcement.
Material Changes and Developments
- Product Milestone: TowerJazz and Axbio Inc. announced the successful development of a microfluidics Bio-CMOS device for molecular in vitro diagnostic (IVD) applications.
- Technology Platform: The device utilizes TowerJazz's advanced 300mm 65nm RFCMOS platform, manufactured at the Uozu, Japan facility.
- Production Timeline: The breakthrough device is planned to enter production by mid-2019.
- Market Expansion: This development expands TowerJazz's RFCMOS presence into the growing IVD systems and medical markets.
Outlook, Management Commentary, and Risks
Management Commentary:
- Dr. Hui Tian (CEO, Axbio) highlighted TowerJazz's flexibility in adapting the 65nm RFCMOS platform to integrate with microfluidic technology, enabling next-generation IVD systems.
- Shimon Greenberg (VP, TowerJazz) stated that the partnership leverages Axbio's IP and TowerJazz's manufacturing capabilities to deliver competitive embedded solutions in multiple markets.
Applications: The platform is expected to support health-related applications including molecular diagnostics, drug discovery, liquid biopsy, microbiology, agriculture, and environmental science.
Risks and Contingencies: The filing includes a Safe Harbor statement regarding forward-looking statements. Actual results may vary due to risks and uncertainties detailed in TowerJazz's most recent Forms 20-F, F-3, F-4, and 6-K, as well as Jazz's Forms 10-K and 10-Q. The company disclaims any obligation to update the information contained in this release.
Investor Verification Checklist
- Verify the actual production start date for the Axbio Bio-CMOS device against the "mid-2019" target.
- Review TowerJazz's most recent Form 20-F for detailed risk factors affecting the medical and IVD market sectors.
- Assess the potential revenue impact of the 65nm RFCMOS platform expansion on TowerJazz's overall specialty foundry portfolio.
- Confirm the status of the partnership agreement between TowerJazz and Axbio Inc. regarding future orders or exclusivity.